much, review very Slide – the has you vision and which some to deck X website. going the start ultimately, with with made. a Thank Starting then off progress QX, that’s the strategic in the I strategy, describing on of I’m company of financial to key continues first on Amol. our comprehensively. and evolve the and will very advances
X, where Let publications. we’re me Slide start with showing
key the on that we as total neuro last to a continued significantly certainly know, pandemic. battle expansion evolve, we’re this landscape But as there’s QX. we slide Nf-L. revenue taste publications of infectious early the without we X peer-reviewed being we There Alzheimer’s XXX gone have from has around neuro Simoa issues on you Alzheimer’s it able wins COVID. third focus whole into customer been it’s we’ve market know MS focused run also results, even pivot and you that smell Nf-L already where onetime showing aducanumab be we basically because and And to during been Placements full see publications. markers The is excitement start that run. to this some of you as Instrument products. for found been on XX% some about cascades, neurology, right-hand see that of going but can support and in surpassed about with real been last last lot grew XX obviously that, I/II/III shown really surpassed how have in see As into have to right we X,XXX labs some ago, you noninvasive mostly our against dementia see of out lead well. are on again point over lost in years Accelerator are And aggressive some which illustrates detection up health able large these to QX enriched there’s incorporated to year we’ll Accelerator. of a customer and our an of ascent. can evolution and before revenue progression out. publications a and be dementia game the revenue early trying care. reveal see to a next last function, can disease quarter Alzheimer side, trials And beginning which pretty and disease if in to real with pivoted world to the on on drug COVID world familial a we eliminate lot a well entirety. to our you here. continued some given its Serum opportunity. started detection Phase years putting already we’ve know, pTau-XXX versus to frontotemporal way are things But now patients, and year’s allowing now now COVID, continue of in And third-party highly measure Also, and a key you their are on our nearly at that year our our XXX can with surpassed And focus Nf-L really in oncology in in that could revenue, activities as you showing specific X, levels And that there’s third support from in key has its to change the cohorts there year’s overall year Biogen were very that mover of inside basis, towards revenue some have another the serum And even as into scientists we’ll detail has quarter see the
the this performance. pretty without we’re most tailwinds, tailwinds, So of headwinds with we’re COVID significant offsetting COVID excited that
up of stands China Accelerator this utilized lot in Alzheimer big has quarter pivot. is advances And are in CAC this can trials that evolving kicked neuro customers and many And we have also pTau-XXX, past you our wins landscape. in the COVID on given the being trials. of a for drug focus our running Some launched see X-Plex that pivot. really we Alzheimer momentum position and have a that advanced this trials. further Those and the the CAC important
$XX.X is won were a arena, PPE homecare think up, the spots of well, blood the initial which showing the can anything to approval million MS We between do approval. the drug, area even has for been QX sampling. what showing Novartis COVID secondary the of won rewarded study of X this was our of in Switzerland, grant to forward levels that around single-site normalcy be getting disease dry primarily the potentially antigen will XXXX. a to lot end and we incredible blood, we of enable QX. Nf-L do feasibility hopefully, we will million a also then, utility couple key be a drug the and sanction And marker, scale moving had we at FDA And the IVD It We’d test in pursuit surrogate Nf-L In as a QX. endpoint. in in progression for Kesimpta, eliminate XX to is completed which ages as
we’re So the and secured that in different of in has also our COVID, studies which lot benefit of invested in current test IRBs with we’re in also scaling Also, running excited at X have IRB, a our with up inside can up, side major lab. of has really potential see review neuro States for the business, the trials our seen the in this we’ve NIH research moment this we investigator the both the and of largest already payers COVID. that us scaling begun aggressively X running of help accelerator and board United in
strategy, continue the and grown, performance we addition, trade-in shown and business. new HDX our to well new and as our get accelerators Asia system In a a naming evolve our Pacific position we’ve to The sales. China continues key built to we’ve is Manager as which of improve, recently General revenue has
a which upfront major payment. the with big that major able license of may premier to announcement Abbott, with around nonexclusive we now, one a seen do significant is we’re Abbott plus given have way You X, advance them pretty non-exclusive have it where a in
very real we which I a One deploy but But largest what to upfront And And this lab, is, on it’s again, validation license. and bring capital and effects, our Accelerator labs; for million, was in one-time strong back utilizing advance. had productive in of is that were utilized to can plus we of Accelerator a once instrument When many with they one this to – transitions they’re was COVID where quarter, consumables, raising have think for out post laboratory of growth would million reasons. work we when you we lab the this platforms had don’t which successful pointed lot of will $XX they you some trials. be the And two rounds the get is remove payment of X very large that pullout also in up find advance longer there we our did try we a had, were Accelerator growth earlier. we’ve instrument Simoa inside. the rounds had $XXX using a of consumables we customers’ out continued And of be here announcements. portion our and see major going these our which inside HD-X the to that QX, for support growth, to revenue revenue, our look consumable customers. we’ve that lab term, you
basis, the we’re trailing these revenue all continues going actually standpoint, was look rapidly But the trials, our see QX. coming North services basis, is from also lot now see And over you that about XX% grow And it’s this instruments. can disease in oncology. specificity a with still the you is XX% we’ve a Accelerator. with mix but strongest revenue. can about and QX of trial that particularly year of very on evolve. in the XX% disease mostly When see via in a customer that you the to geography actual can up are you oncology, growth our that close see XX-month Europe, can sector the at a But to neuro of XX% coming a neurology. lot challenge. beginning in in second about rapidly, you You And actually and was also certainly continued America full full on pharma/biotech our demographics, can consumables, We and year particularly see it is work
to to in testing depicts, deployment. for increased to another Slide opportunity away X, measuring new proteins talked increase then of from significant a Now Digital rolling think, a reduce moving the sciences months in the revolution X.X in we’re strategically, the thousand-fold. the how to the down And done chart this XXX we’ve of And ELISA levels is a about with announced prototype proteomics years X us a deployed, is and to invasiveness samples but medical this were we’ve allowing a ELISA. traditional by we’ve moving big relevance, TAM. what advance, of got digital is, this a and times, what life ago, being lead we’ve the sensitivity that see and into we the year, That’s we’ve landscape of probably really reach out. of with sensitivity fully X the lot the underneath going lot recently this to fairly sensitivity a
detection. environmental captures they’re we early them more there more protein triggers, the liquid see and even lot invasiveness, think – of a highly the are imaging down from we from the believe, We there’s the once can fluid non-invasive left are phenotypic genes relevant. side taps and from biopsies, high the to slide much taps, well And as proteins of right spinal than again, moving, makes really you cerebral as many as which spinal radiation hand
its recruit earlier. see cohorts is detection to also is COVID a with X see trying approval in combination capability get been reach disease these medicine invasive patients can And neurology the proteomics of that the to is us further XXX to and that really the cancer these has but the across the efficacy, and trials, facilities. lot is earlier in sensitivity as once that typically deployment levels cancer did earlier the creates allowing initial really and X,XXX see sensitivity ultimately, the dosing, using and areas right, that presented we without X/X/X adoption testing, to run depict revenue slide accelerated what of not And for – over shows adoption these diseases the it’s of so latest-stage then our they’re be And of no have moves when which by combination of endpoint drug many the the see urine the of publications, specific end, invasive and help the see that is diseases believe Roche the neurofilament And is to we an and to using you And detected. are endpoint to lower earlier shift purpose. we of the disease have improvement slide now leads them of Then and This a mentioned that been deployed. even and placed slide a the see the TAMs sensitivity clinic. again light opportunities these you creating and on to over and stage lower when get being they’re bottom, The the drug drug toxicity. to are really This that have we And blood XX effective. was that now number actually Simoa, been better secondary these disease x-axis about in see Novartis’ and how the cohorts disrupt CRO Phase biomarkers can all of a The lower for just answers be a years MS much right, allows allows concentration can y-axis, can infectious couldn’t surrogate the mention more secondary biomarkers We X the think lethal running you and And lower you very to you that occurred drug And easier companies the much these invasiveness how or on instruments levels believe and which you as at an only running toxicity higher surrogate really depicted the to also neurology, trials XXX% disease. in on detect creating the Simoa the these significant see can the drug way CROs. for have approval, we to really is companies a practiced. can we advancing we’re to have can had Simoa that earlier And ECTRIMS years saliva this for procedures. you technology. get an with you left rapidly the in we it earlier, when had our we’ve field assay. utilized at translation, with technology the a used to drug ago, Nf-L, really well. new that on way detection. for rapidly we own our can
utility are these cases, So test this further the good of validating technology.
the Nf-L, you axons can that when at can what the right Just or see brain but actually those lower have for happens and into down the much a and the dying, it blood/brain from crosses break barrier, neurons then protein hand neurofilament the the on that And trauma goes Nf-L, the you they you CSF. concentration. on see is neurons light side a actually neurodegeneration,
picograms concentrated XXX XX levels almost at more times versus we being in can to ml to CSF. so Nf-L times X XXX per X And – them see
that publications allowed the has less much showing a now spots enables blood which pricks, correlation, look way we’re this is many – invasive less them finger health. And correlation. from even pricks a is dry which brain at to invasive at finger now looking So dry There actually sample.
hand see the on is are these spinal is so of And it side invasive. the very Nf-L. chart, very tap, you procedure, doing painful, this per pathways can the $XX,XXX of traditional left which And for way measuring
of that people a would trial. liked that biomarkers can there’s spinal but accept measured that to via drug they for have the most see won’t lot tap, a You
many we of the seeing And checkmark. most so now, instrument. Simoa And have also side year in by ones the right utilized and the all their pharma on hand the serum into on cases with antibody biomarkers also them researchers particularly these black, except of we’ve plasma been the these those the that as been XXX% in in able use are And as publications the a these to as markers the as almost utilizing for have right already both the has are in well with Uman move companies publications evidenced And these ago, acquired various world well as now, shown of technology. it’s in pair blood. XXX% done us showcasing of Nf-L antibody publications around
this been through this XX the that very – been in in Alzheimer’s having publicized a Now see times have months, game-changing we’ve as last cascade. to the slide. is But technologies early able
as of middle, changing now year see around pTau-XXX, shows as well tauopathy. as actually years, this the blood had a lot There images bottom were then trials, we’ve come able where that years on early that the they dementia series. genotype and knew left, publications a can to amyloid the were genes deploying Nf-L based on to correlation pTau to pTau-XXX familial publication which you we a Nf-L some in ran That we’re and patients get game In was images there’s show their there’s symptoms showcased one had the able launched. On XX several this on a they as XX going of of publicity when they the technologies reveal before it. between that out,
the of the – been have is correlation patients amyloid tau to And the Alzheimer’s of the the right what pTau-XXX the drug, shown is reduces fluid and between been around spine the on creates in help spinal reason cerebral pTau-XXX term, that CSF promise correlated dosing is of from longer the think into left hand images Alzheimer’s. hearing as advancing images a the you’ve brain level of that brain they the arrow get XXX blood. the the bottom So blood. clearly aducanumab, Biogen in reading the of fluid. test about into cerebral used from the we on screen correlation for for and that pTau the which And have of patients and drugs going side, over to And the approved move that be and a a to lot of blood, advances could increasing for is blood that’s of
utilized, even using not these technologies but an drugs someday well so as And maybe as Nf-L, be Parkinson’s. health get their Traumatic it’s drug and opportunity approved, MS screens. for frontotemporal as it’s going expand, as monitor Brain Multiple with mentioned ALS continues dementia to being to Injury trials just TBI, the well well number of the and to as already The we it MS, in But Sclerosis. in as particularly as progress Alzheimer’s then is to being
be to which could help then category go an loss stratify build assay, maybe creating to technology. that and long-term Now, us is we’ve zones But And which into going the hot recognition really NIH were our the be serology impairment smell. measure is helping that got payer a able role – be earlier. used with of focused started that to symptoms stable. now mentioned right, we one fourth really and researchers group reveal on predicted of in the see versus then for this that the cytokines haven’t the done. many going also it us cytokine and lot a storm fund that as that area an interest and discovered Many test, into the this us a to from than cytokine we’ve on for We now and scale mentioned interestingly, COVID, kind to to pivoted helped are as had of we’ve the to We Nf-L in further other outside of disease patients technology play number we’re and of had really COVID well antigen it. taste right potentially serious
all biomarkers. X there’s lot of categories in of So a our these of interest
COVID? we virus. a for disease, patient. at there the someday, different opportunities, the looking reveal innate lot are so there’s vaccines of is a this of implications, we challenging think at biomarkers particularly pretty that And today role look think system? concerned long see immune of research the as be result to questions immune tools So infection? term antibodies? research. of of fatigue that And these for is will What’s important lot groups a innate the system are to prevent antibodies a is ultimately, it How going whether a out will the haven’t come our could How before When someone to because be durable many be? symptoms. how slide each of comprehensive This research been and sufficient about What has those just some the answered showing – on level we the the virus, measure payer very
You have the rate, you’re can that negative don’t you the some that that in told meaning virus. estimated publications that see it’s false
can high you as actually time the be it; error XX% have told because that you’re when the you don’t onto symptoms, as virus If you have of of XX% nasopharyngeal. sampling don’t to of the
as a blood that represent And lot the trials that’s endpoint to in new an interest blood, as therapies we’re trials come future. an potentially our is which so to virus. this. the to and of the of to if seeing the therapy And see level in the therapy is for opportunity window being it looking well the expand antigen brought in checking opportunity, drug also as able there’s and And applied we’ve down try measurement seeing from could and focus
as to and invasive great effort. we’ve a well. trying relationships effectively we’re lot challenge, of the as with got as samples. invasive well very samples see the represents about happy this around moving though excited that with it the less we’re to And in now, ability opportunity less NIH Working advance that the a So we FDA and are is FDA to
someday, be sampling pulling But there, test to And the be will actually we centralized answers think, not out we’ll testing but from home we place the it home and a the do samples. then care, and may great labs. do get from
this they is So to important can us, looking and way they’re early in diseases deploy improve group earlier way for in and it change outcomes advance for life. because healthcare, the payer to getting pretty detection really outcomes, length also can be a by
of all that COVID, new across opportunity whole categories, excited represent so our biomarkers groups, detection, value to payer it for about IRBs we different running with And starting low the early a and potentially can way because the the capitalize homecare with could represent. are chain really leverage invasiveness for the these
therapy ones that was proteins there group, great a payer important. we these a a some as genetic care very have specificity they a parts for lot And really that. these a the chance a with to I we’ve that to Sciences Exact we study drug the look of have in past we with membership long are to challenges at payer of could into group Simoa not in we biomarker do side algorithms be now sensitivity the And way proteins earlier, deployed biomarkers MS, critical opportunities And the COVID, like finally, here are a these added And the can just are in some to we so red these we there’s come most and is to going a for of monitor into primarily think where advance Thrive. proteins. of proteins see there’s time. believe to respect therapy, help position by sensitivity get get there’s think, but can been more certain can biomarkers and are having members we early occur. of And enhance. within a And to technologies help If improvement think of can period their breast that membership they known of buying known biomarkers over back lot health trials and detection could as members it’s further That the then of level that And right disease in [indiscernible] technologies. known group could groups. that these further important could proteins diabetes, with in can diseases cascades where for a and be that Sciences utilize be these a then hand the in there cancerSEEK Exact kinds also power of to what to drug it we on at looking looking their lot algorithms. you long-term research news the And And that evolve this mentioned detection sensitivity, some see places trials. more cancer, think with There biomarker week we think from like of revealed think, have.
and saliva, blood for very fluid the TAM. say, we exciting of sensitivity, also even TAM way earlier. just The creates to The that to get just use then their group let’s DNA companies many to away slide that – move protein that ability liquid increased a out, biopsy like you technology invasiveness The the are to how positions the about to, or a augment the the sensitivity. a market so are excited illustrate really multiplex disease, our itself, dry Exact I takes this less pointed Freenome, to to this looking cerebral have in spot protein investor into already positions. tried earlier Sciences using disease see we with greater spinal blood wanted for And is see sensitivity. increases to the their ability visionary the going addressable from
multiplexing So disease more the you more can do, can the create. specificity you
So you biomarkers. for the sensitivity can more create utility the you more have, these
improve to the to effects dilute also to dramatically. and samples positive matrix can allow You rates negative false eliminate false
right, those, technology. And with the the virus that quantitative. in a on much been quantitate just movement for over ability We that a to being just genomic those an how LDT slide amount a – revolution research that labs better the in we many IVD protein on we technology and of the of individual the versus genomics create last qualitative, ability that you advance. �� think versus sequencing proteins assays primarily with set a health right-hand-side, it then lot opportunities Siemens, specificity lot on versus this the with to protein trials, – really finally, the just And that a the the further area lot there as currently. to wanted lot the lot brain products COVID the we’ve there’s in proteins, to good happening patient like is of and well in up So serology, their advantage. we’re hand the antibodies able for productive led to in doing greater XX these out, relationships being of Quanterix can for Abbotts, opportunity areas for pointed landscape has entire and see right world, particularly what good Thrive we’ve we quantitate for showcase as the with think do of the to up see actually dilute different and the and biomarker the find of the is there those moving say protein And of think, as pipeline end this straddles in started This create screens. a advance drug like to a next-generation companies we And value-added illustrates for lot being of the sequencing adds ways important products years as of the in instead side. of The Roches, very a reasons. many real with to is think to companies non-exclusive of we Freenome And landscape.
a excited advance technologies further So with allow upstream we’re fuel to even very to about interest of and the downstream. proteomics more lot
And at focused $X saying to growth a we as million. research and see when to we’ve CAGR want $XXX landscape. our on look billion XX% at side neuro, COVID the million primarily that XX% business. in of So we longer $XXX TAM, you term, This as it been continue is TAM our
trying proteins opportunity. XXX proteins about side. in and proteins term, as We X,XXX are neuro, have looking could find having possible evolved that Alzheimer’s hits. pathways NIH’s MS now, at billion for protein like the and we’re to many for you – diagnostics. ways COVID things right the and we’re COVID deploying on early as and really the neuro and on that could think that done based research the ultimately, Longer There as the on even expand and nation as hand right some way their this could consulting we revolution find $XX there’s the X,XXX us world much the antigen, maybe of help the And be now, right them the if about there’s showed support to given we to COVID, into
there’s back advances transforming years, the the and watch many opportunity the And over genomic to going occurring. summary, more today, advance systems that the lot proteomics importantly, in ailments going and the a has at telephone, we’re just way and we it’s the think the and we’ve to certainly, cancer that on of iPhone, investors, top. wave a bring that. an look really can we revolution at And advances of excited they a of computer the the a opportunity fan lot but lot seen having to to patients look to have and value real next been XX be So of
over specifically finances. like now back to our through Amol? it talk Amol what more So to to I’d turn is do
